Pre-made Oportuzumab benchmark antibody ( scFv, anti-EPCAM therapeutic antibody, Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Oportuzumab biosimilar, scFv, Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

A fusion protein immunotoxin consisting of a humanized, single-chain monoclonal antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) conjugated with a truncated form of Pseudomonas exotoxin A with potential antineoplastic activity.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-408-1mg	1mg	3090
GMP-Bios-ab-408-10mg	10mg	Inquiry
GMP-Bios-ab-408-100mg	100mg	Inquiry
GMP-Bios-ab-408-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Oportuzumab biosimilar, scFv, Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody
INN Name	Oportuzumab
Target	EPCAM
Format	scFv
Derivation
Species Reactivity	Human
CH1 Isotype	na
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Preregistration
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2008
Year Recommended	2009
Companies	University of Zurich;National Cancer Institute (USA);Sesen Bio;Viventia Biotechnologies
Conditions Approved	na
Conditions Active	Bladder cancer;Head and neck cancer
Conditions Discontinued	Liver cancer;Ovarian cancer
Development Tech	na